Chinese Regulator Approves Sino Biopharmaceutical's Alzheimer Treatment Patch for Marketing

MT Newswires Live09-25

Sino Biopharmaceutical (HKG:1177) obtained approval for marketing for Rivastigmine Transdermal Patch from the National Medical Products Administration of China, a Wednesday Hong Kong bourse filing said.

Trading under the name Debaitai, the patch is for the treatment of symptoms of mild-to-moderate Alzheimer's disease, a neurodegenerative condition with severe onset and progressive impairment, and a major cause of senile dementia.

Rivastigmine transdermal patch can supply a sustained and stable release of drug over a longer period, even for the patients who can not take oral medicines.

Price (HKD): $3.43, Change: $-0.030, Percent Change: -0.87%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment